Introduction {#Sec1}
============

Intracranial berry aneurysms (IBA) develop in the walls of cerebral arteries where the endothelial layer has weakened and formed a sac-like abnormality. IBA are also referred to as saccular aneurysms and differ from other intracranial aneurysms in shape, forming an out-pocketing off of a cerebral artery, reminiscent of a berry on a vine. Fusiform aneurysms involve dilatation of the entire vessel wall for some component of its length; in the cerebral circulation they are much rarer that berry aneurysms (Park et al. [@CR85]). It is estimated that 3 % of the general population have at least one IBA (Rinkel et al. [@CR88]; Vlak et al. [@CR113]), a prevalence that increases to 3.6--6.5 % in people over 30 years of age (Krischek and Inoue [@CR54]). Aneurysmal rupture accounts for a significant proportion (80--85 %) of subarachnoid hemorrhage (SAH) (Brown and Broderick [@CR17]). SAH is fatal in 35--50 % of patients, and leads to permanent brain damage in 25--50 % of survivors (Rinkel and Algra [@CR89]; Ronkainen et al. [@CR92]; Rosenorn et al. [@CR94]; Schievink [@CR101]). Population-wide screening is not currently recommended, as most cerebral aneurysms are asymptomatic and will never rupture (Ronkainen et al. [@CR92]). From a genetic epidemiology perspective, IBA are considered to be a common, complex condition with multiple risk factors including advanced age, ancestry, sex (women affected more often than men), smoking, longstanding hypertension, and family history (Brown et al. [@CR18]; The International Study of Unruptured Intracranial Aneurysms Investigators [@CR107]; Juvela et al. [@CR45]; Leblanc [@CR56]). Familial intracranial aneurysms (FIA), a hereditary subtype of IBA, is suspected when two or more affected first- to third- degree relatives are present in a family (Fig. [1](#Fig1){ref-type="fig"}a and b) (Bederson et al. [@CR8]). Differences in study populations and methodology have contributed to variability in the reported prevalence of FIA. For example, the rate of detection of intracranial aneurysms when screening first-degree relatives with at least two affected family members has been reported to be 9.2--9.8 % in patients older than 30 years, which is approximately 2--3 times higher than the risk within the general population (Ronkainen et al. [@CR92]; [@CR91]). A more recent study screened for aneurysms among asymptomatic first-degree relatives of families with two affected first-degree relatives *or* three affected second- to third- degree relatives, and found detection rates as high as 20.6 % among patients older than 30 years (Broderick et al. [@CR15]). Individuals with FIA seem to have a more severe phenotype: they are more likely to develop more than one brain aneurysm (Brown and Broderick [@CR17]; Rinkel et al. [@CR88]), and have 17 times greater risk of rupture compared to those with sporadic IBA (Broderick et al. [@CR15]). Furthermore, aneurysms that do rupture tend to rupture at a younger age and at a smaller diameter among patients with FIA (Bacigaluppi et al. [@CR7]; Broderick et al. [@CR15]; Lozano and Leblanc [@CR62]). Along with the increased risk for aneurysm formation and rupture, patients with FIA appear to have a poorer outcome after rupture (Bromberg et al. [@CR16]; Kojima et al. [@CR52]). Generally, screening with magnetic resonance angiography (MRA) or computerized tomographic angiography (CTA) is recommended for individuals with two or more first-degree relatives diagnosed with intracranial aneurysms (Bor et al. [@CR12], [@CR13]; Brisman et al. [@CR14]; Brown et al. [@CR18]; Ronkainen et al. [@CR92]; Thompson et al. [@CR108]). In the absence of prospective longitudinal studies, expert consensus appears to be that relatives at sufficient risk to merit screening should begin such screening 10 years prior to the earliest age-at-diagnosis in their pedigree.Fig. 1Pedigrees of three families diagnosed with familial intracranial aneurysms suggesting dominant inheritance (**a),** and inheritance consistent with dominant or X-linked transmission **(b**). Part (**c**) shows a sporadic case of an intracranial berry aneurysm; its onset in childhood in the absence of known environmental risk factors is consistent with a major genetic risk factor such as a de novo pathogenic variant

For the benefit of genetic counselors, who may be consulted by patients concerned about their risk for intracranial aneurysms, or who may discover a family history of intracranial aneurysms during a routine session, we present here a review of the genetics of IBA, and of the known Mendelian syndromes that confer increased risk for IBA. For a review of the natural history of IBA and options for treatment, we refer interested readers to the American Heart Association/American Stroke Association 2015 Guidelines (Thompson et al. [@CR108]) and to a recent review article by Brown and Broderick ([@CR17]).

Family Mapping Studies {#Sec2}
======================

Familial mapping studies have been done in large pedigrees that appear to have a single genetic variant as a major risk factor for intracranial aneurysm development. Mapping follows the hypothesis that such a variant will be found in a chromosomal region that has been commonly inherited by all affected family members. Markers of known genomic location, such as single nucleotide polymorphisms (SNPs), are used to derive haplotypes that can in turn be used to identify loci that co-segregate with FIA. Investigations of families and affected sibling-pairs have suggested numerous loci associated with FIA (Table [1](#Tab1){ref-type="table"}). From these studies the loci with the strongest association are 7q11, 19q13, and Xp22. (Farnham et al. [@CR29]; Foroud et al. [@CR32], [@CR33]; Kim et al. [@CR50]; Mineharu et al. [@CR69]; Nahed et al. [@CR74]; Olson et al. [@CR82]; Onda et al. [@CR83]; Ozturk et al. [@CR84]; Roos et al. [@CR93]; Ruigrok et al. [@CR98]; Santiago-Sim et al. [@CR100]; van der Voet et al. [@CR110]; Verlaan et al. [@CR112]; Yamada et al. [@CR117]). A recent meta-analysis of five familial mapping studies revealed an additional two loci in linkage disequilibrium with FIA, 3q27.3-3qter and 17p12-q21.33 (Biros and Golledge [@CR10]). A SNP association study aimed at replicating loci previously flagged by linkage analysis confirmed the association at 14q23 (found by (Ozturk et al. [@CR84])) in a cohort of 266 affected and 288 unaffected Japanese individuals (Mineharu et al. [@CR70]). The number of loci identified though linkage analysis indicates there is genetic heterogeneity in FIA.Table 1Loci associated with familial intracranial aneurysms by linkage analysisAssociated LociStudy Population(s)OMIM Locus nameOMIM numberStudied in \> 1 populationStudy Cohort \[affected (unaffected)\]References1p36.13-p34.3North American, DutchANIB3609,122Yes12(8) from 1 family\
7(10) from 1 familyNahed et al. ([@CR74])\
Ruigrok et al. ([@CR98])2p13Dutch\--No7(9) from 1 family^a^Roos et al. ([@CR93])4q32.2FIA Study\--Yes192 families^b,c^\
333 families^b,c^Foroud et al. ([@CR32])\
Foroud et al. ([@CR33])5p15.2-p14.3French-CanadianANIB4610,213No9(3) from 1 familyVerlaan et al. ([@CR112])5q22--33Japanese\--No104 ASP from 85 familiesOnda et al. ([@CR83])7q11.2Japanese, North AmericanANIB1105,800Yes104 ASP from 85 families\
39(0) from 13 familiesOnda et al. ([@CR83])\
Farnham et al. ([@CR29])8p22South KoreanANIB11614,252No9(22) from 5 familiesKim et al. ([@CR50])11q24-q25Colombian, North AmericanANIB7612,161Yes2 families^b^Osturk et al. (2006)12p12.3FIA Study\--Yes333 familiesForoud et al. ([@CR33])13q14.12-q21.1French-Canadian\--No10(25) from 1 familySantiago-Sim et al. ([@CR100])14q22Japanese\--No104 ASP from 85 familiesOnda et al. ([@CR83])14q23Colombian, North AmericanANIB8612,162Yes2 families^b^Ozturk et al. ([@CR84])17cenJapanese\--No93(27) from 29 familiesYamada et al. ([@CR117])19q13Finnish, JapaneseANIB2608,542Yes48 ASP from 22 families\
222 ARP from 121 families\
93(27) from 29 families\
41(0) from 9 familiesOlson et al. ([@CR82])\
van der Voet et al. ([@CR110])\
Yamada et al. ([@CR117])\
Mineharu et al. ([@CR69])Xp22North American, Japanese, DutchANIB5330,870Yes48 ASP from 22 families\
93(27) from 29 families\
7(10) from 1 familyOlson et al. ([@CR82])\
Yamada et al. ([@CR117])\
Ruigrok et al. ([@CR98])Study cohort data corresponds with the reference in each horizontal row. *ASP* Affected sib-pair; *ARP* Affected relative pair^a^Family is consanguineous^b^The number of affected and unaffected individuals included in the linkage analysis was not available^c^A total of 1155 affected and 1895 unaffected family members were genotyped in Foroud et al. ([@CR32]) and Foroud et al. ([@CR33]). Families were enrolled at recruitment sites located in North America, New Zealand, and Australia

Genome-Wide Association Studies {#Sec3}
===============================

Genome-wide association studies (GWAS) interrogate the genome for statistically significant associations between SNPs and disease at a population level. Several loci have been associated with sporadic IBA by GWAS, primarily using large discovery and replication cohorts from the Dutch, Finnish, and Japanese populations (Table [2](#Tab2){ref-type="table"}) (Abrantes et al. [@CR3]; Bilguvar et al. [@CR9]; Deka et al. [@CR26]; Foroud et al. [@CR34], [@CR35]; Kurki et al. [@CR55]; Low et al. [@CR61]; Yasuno et al. [@CR119], [@CR120]). The most frequently replicated locus is 9p21.3, which contains the long non-coding RNA, *CDKN2B--AS1*, and is adjacent to the cyclin-dependent kinase inhibitor genes, *CDKN2A* and *CDKN2B*. The same linkage block in 9p21.3 associated with IBA has also been associated with other vascular diseases, including coronary artery disease, myocardial infarction, and abdominal aortic aneurysms: this suggests that there may be a single locus that predisposes to all of these conditions via a common pathology (Helgadottir et al. [@CR40], [@CR39]). Alg et al. ([@CR5]) conducted a meta-analysis of 61 GWAS studies that replicated the association between three loci (9p21.3, 8q11, and 4q31.23) and IBA. In contrast to the postulated high-penetrance Mendelian loci in FIA, loci discerned through GWAS each have a relatively small effect size on the risk of developing IBA. For example, SNPs at the strongest associated locus, 9p21.3, have reported odds ratios between 1.29--1.34 in the major GWAS studies (Bilguvar et al. [@CR9]; Foroud et al. [@CR35]; Yasuno et al. [@CR120]).Table 2Loci associated with intracranial berry aneurysms through genome-wide association studiesAssociated LociStudy Population(s)OMIM Locus nameOMIM numberReplicated in \> 1 populationSize(s) of Study CohortReferences2q33.1Dutch, Finnish, JapaneseANIB9612,586Yes2196 cases; 8085 controlsBilguvar et al. ([@CR9])4q31.22Japanese\--No2431 cases; 12,696 controlsLow et al. ([@CR61])4q31.23Dutch, Finnish, Japanese\--Yes5891 cases; 14,181 controlsYasuno et al. ([@CR120])\
Yasuno et al. ([@CR119])5q31.3Finnish, Dutch\--Yes2335 cases; 9565 controlsKurki et al. ([@CR55])8q11.12--12.1Dutch, Finnish JapaneseANIB10612,587Yes2196 cases; 8085 controls\
5891 cases; 14,181 controls\
406 cases; 392 controls\
1483 cases; 1683 controlsBilguvar et al. ([@CR9])\
Yasuno et al. ([@CR120])\
Deka et al. ([@CR26])\
Foroud et al. ([@CR34])8q21.3Dutch, Finnish, Japanese\--Yes5891 cases; 14,181 controlsYasuno et al. ([@CR120])9p21.3Dutch, Finnish, Japanese, PortugueseANIB6611,892Yes2196 cases; 8085 controls\
5891 cases; 14,181 controls\
406 cases; 392 controls\
1483 cases; 1683 controls\
4133 cases; 7869 controls\
2431 cases; 12,696 controls\
200 cases; 499 controlsBilguvar et al. ([@CR9])\
Yasuno et al. ([@CR120])\
Deka et al. ([@CR26])\
Foroud et al. ([@CR34])\
Foroud et al. ([@CR35])\
Low et al. ([@CR61])\
Abrantes et al. ([@CR3])10q24.32Dutch, Finnish, Japanese\--Yes5891 cases; 14,181 controlsYasuno et al. ([@CR120])12q22Dutch, Finnish Japanese\--Yes5891 cases; 14,181 controlsYasuno et al. ([@CR119])13q13.1Dutch, Finnish Japanese\--Yes5891 cases; 14,181 controlsYasuno et al. ([@CR120])18q11.2Dutch, Finnish, Japanese\--Yes5891 cases; 14,181 controlsYasuno et al. ([@CR120])20p12.1Dutch, Finnish, Japanese\--Yes5891 cases; 14,181 controlsYasuno et al. ([@CR119])The size of each study cohort corresponds with the reference in the same horizontal row. Yasuno et al. ([@CR120]) and Yasuno et al. ([@CR119]) analyzed the same discovery and replication cohorts, which were expanded on from the cohort studied in Bilguvar et al. ([@CR9])

Next-Generation Sequencing Studies {#Sec4}
==================================

Unlike GWAS, but similar to linkage analysis, whole-exome sequencing (WES) aims to identify rare variants that have a large effect size and impart a high risk of developing intracranial aneurysms. Recently, three WES studies of multiplex families diagnosed with FIA have revealed new candidate genes in the development of intracranial aneurysms. All three studies excluded individuals who were diagnosed with a syndromic form of IBA.

The Familial Intracranial Aneurysm (FIA) Study published two exome sequencing studies on seven multiplex families of European-American ancestry. These families were selected for having high numbers of affected individuals, and for having pedigrees consistent with either autosomal dominant or autosomal recessive inheritance. Initially, WES was carried out on 50 affected and unaffected individuals from these families, and analysis identified 96 candidate genes (Foroud for the FIA Study Investigators [@CR31]). In their second publication (Farlow et al. [@CR28]), the FIA Study researchers analyzed WES data from 36 affected and 9 unaffected family members. Unaffected family members were only included if they were above 45 years of age and had received a negative screen by MRA. It is of course possible that some of the family members who were scored as unaffected may yet develop an IBA in their lifetime. For this analysis, Farlow et al. ([@CR28]) employed six biological filters on their WES data to generate a list of 68 candidate variants in 68 genes. These filters examined the variant type (non-synonymous SNVs or exonic and splice site indels), variants with a minor allele frequency (MAF) of \<0.01, the segregation within families, and the predicted effect on protein (via CADD score ≥ 10, and predicted damaging by Polyphen2 or SIFT). Five variants, found in *GSTCD, DUSP16, LMBR1L, HAL* and *TSC2,* segregated fully with disease in one family and were present in the affected individuals of a second FIA family. None of the variants found in this study overlapped with any GWAS flagged loci (Farlow et al. [@CR28]). This is presumably because rare, highly-penetrant pathogenic variants that result in a Mendelian inheritance pattern in a multiplex family tend not to spread through to the general population (unless some sort of balancing selection occurs).

Yan et al. ([@CR118]) had broader inclusion criteria and sequenced families with three or more affected first- to third- degree relatives. They sequenced 42 affected people from 12 families of Japanese ancestry. After filtering for their presence in all affected family members, minor allele frequency (MAF) \<0.05, and a predicted damaging effect to the protein (Polyphen2 and SIFT), WES analysis resulted in 78 candidate variants. Two variants, p.Y193F in *GPR63* and p.R142H in *C10orf122* (*TEX36*), segregated with affected individuals in more than one family. While both of these protein changes are predicted to be deleterious, relatively little is known about the gene function and there was not sufficient evidence to classify either mutation as pathogenic. Yan et al. ([@CR118]) then selected ten variants from nine genes, based on functions that were plausibly associated to the pathogenesis of intracranial aneurysms, for Sanger sequencing and replication in two additional Japanese cohorts. The first replication cohort consisted of probands from 24 independent FIA families, and the second replication cohort included 426 individuals diagnosed with sporadic IBA. A variant in *ADAMTS15* was significantly associated with the familial cases in the first replication cohort, while variants in *THBD, IL11RA, PAFAH2,* and *ZNF222* had a slightly increased MAF among the sporadic IBA cases in the second replication cohort compared to the Japanese population.

For rare diseases with characteristic phenotypes, a gene-disease association is established when rare variants are present in the same gene in three independent families. For more common diseases such as IBA, issues such as non-penetrance and phenocopies make additional evidence (such as functional studies) highly desirable in order to lower the false discovery rate. Whereas none of the candidate genes yet flagged through these WES studies have sufficient genetic evidence to prove a causal association, genes containing variants that co-segregate with disease in multiplex families are the best candidates to date, and may be implicated (or discarded) by future next-generation sequencing studies.

Syndromes Conferring Susceptibility to IBA {#Sec5}
==========================================

Autosomal Dominant Polycystic Kidney Disease {#Sec6}
--------------------------------------------

Apart from family history, diagnosis of autosomal dominant polycystic kidney disease (ADPKD) imparts the highest risk for developing IBA (Table [3](#Tab3){ref-type="table"}). Between 4 % and 17 % of patients with ADPKD will develop IBA, with an equal risk distribution between genders (Chapman et al. [@CR19]; Huston et al. [@CR43]; Niemczyk et al. [@CR78]; Ruggieri et al. [@CR97]; Xu et al. [@CR116]). As seen with non-syndromic IBA, the prevalence of IBA increases with age in this disease (Niemczyk et al. [@CR78]; Xu et al. [@CR116]). The combined risk for aneurysmal formation in patients diagnosed with ADPKD and a family history of IBA or SAH increases to approximately 22--25 % (Huston et al. [@CR43]; Ruggieri et al. [@CR97]). Screening for IBA in ADPKD is recommended in patients above 30 years of age, or in patients with a family history of IBA (Xu et al. [@CR116]). Hypertension, found commonly in ADPKD patients, is not considered to be an obligatory risk factor for aneurysm formation in this context. Individuals with ADPKD who have well-controlled hypertension, or hypertension within a normal range, have still been seen to develop intracranial aneurysms (Chauveau et al. [@CR20]; Gieteling and Rinkel [@CR37]; Niemczyk et al. [@CR78]; Xu et al. [@CR116]). Pathogenic variants in the *PKD1* and *PKD2* genes are causative for ADPKD and account for 85 % and 15 % of diagnoses, respectively (Niemczyk, [@CR77]). Patients with pathogenic variants in *PKD1* or *PKD2* appear to have an equivalent risk of IBA (Rossetti et al. [@CR96]). *PKD1* and *PKD2* mutations cause defects in the mechanosensory cilia found on renal and vascular endothelium, which leads to cyst and aneurysm formation, respectively (AbouAlaiwi et al. [@CR2], [@CR1]; Nauli et al. [@CR75], [@CR76]). Patients with tuberous sclerosis complex can also have a concurrent diagnosis of ADPKD when their disease is caused by a contiguous gene deletion affecting *TSC2* and *PKD1* at chromosome 16p13.3. These patients not only have more severe kidney disease, but are also at risk for intracranial aneurysms (Chen et al. [@CR21]; Longa et al. [@CR60]; Sampson et al. [@CR99]).Table 3Prevalence of intracranial aneurysms in selected syndromes and their associated gene(s)Relative PrevalenceSyndromeOMIM Number(s)Prevalence of patients with IBAAssociated GenesFrequentAutosomal Dominant Polycystic Kidney Disease173,900\
613,0954--17 %*PKD1, PKD2*InfrequentVascular Ehlers-Danlos Syndrome130,05012%^a^*COL3A1*Loeys-Dietz Syndrome609,192\
610,16811--28 %^a^*TGFBR1, TFGBR2, SMAD3* ^b^Marfan Syndrome154,70014%^a^*FBN1*Neurofibromatosis Type I162,2009--11 %^a^*NF1*Rare ^c^Pseudoxanthoma Elasticum264,800-*ABCC6*Hereditary Hemorrhagic Telangiectasia187,300\~10%^d^*ENG*Multiple Endocrine Neoplasia Type I131,100-*MEN1*^a^Prevalence estimates may be influenced by selection bias and the inclusion of both fusiform and berry aneurysms^b^Pathogenic variants in *TGFB2* and *TGFB3* also account for \<5 % of LDS cases^c^Individual case reports only^d^As the prevalence of IBA in HHT patients is unknown, the prevalence of arteriovenous malformations, which can also lead to cerebral hemorrhage, has been given

Ehlers-Danlos Syndrome {#Sec7}
----------------------

Ehlers-Danlos syndrome (EDS) is an autosomal dominant connective tissue disorder. In classical EDS, the majority of patients have pathogenic variants in *COL5A1* and *COL5A2*, while in vascular EDS, previously referred to as EDS Type IV, variants in *COL3A1* are responsible for disease (De Paepe and Malfait [@CR25]). Vascular EDS patients have a high risk of mortality due to vascular fragility that often leads to hemorrhage (De Paepe and Malfait [@CR25]). Intracranial aneurysms have been reported in both classical and non-classical forms of EDS, but relatively speaking it is patients with the vascular subtype of EDS who are at the highest risk for IBA formation (Chen et al. [@CR22]; Kato et al. [@CR47]; Kim et al. [@CR51]; Lummus et al. [@CR65]; Mirza et al. [@CR71]; Oderich et al. [@CR80]; Schievink et al. [@CR102], [@CR103]). Kim et al. ([@CR51]) found intracranial aneurysms in 12 individuals, seven of whom had vascular EDS, from a chart review of 99 EDS patients (mean age 41.7 years) who underwent brain imaging. There is currently no consensus on the clinical utility of screening for intracranial aneurysms among otherwise asymptomatic vascular EDS patients. Results of a positive test on such screening may not be easily actionable, because of the high risks associated with surgical intervention. If screening is desired, a non-invasive approach (such as MRA) should be strongly considered in these patients, in order to avoid further weakening of the vasculature (North et al. [@CR79]; Oderich et al. [@CR80]). Certain tertiary care centers with specialized expertise have reported low rates of complications from endovascular procedures in EDS (Lum et al. [@CR63], [@CR64]), such that screening may be safe for EDS patients receiving care at experienced centers.

Loeys-Dietz Syndrome {#Sec8}
--------------------

Loeys-Dietz syndrome (LDS) is a connective tissue disorder characterized by severe vascular defects, primarily arterial aneurysms, that can hemorrhage or dissect very early in life (Loeys et al. [@CR58]; Williams et al. [@CR115]). Autosomal dominant mutations in TGF-β pathway genes, most frequently *TGFBR1* and *TGFBR2,* cause LDS. Although LDS is not commonly listed as having an association with IBA, a number of patient cases have reported IBA as a feature (Hughes et al. [@CR42]; Levitt et al. [@CR57]; Loeys et al. [@CR58], [@CR59]; Rodrigues et al. [@CR90]; Williams et al. [@CR115]). Cerebrovascular bleeding is the third leading cause of death in LDS patients, and intracranial aneurysms have been seen at a frequency ranging between 10 and 28 %. (Kim et al. [@CR51]; Loeys et al. [@CR59]; Rodrigues et al. [@CR90]; Vanakker et al. [@CR111]). Although further studies are needed to assess the clinical utility of screening LDS patients specifically for intracranial aneurysms, surveillance of each part of the vascular tree is currently recommended every two years (MacCarrick et al. [@CR66]).

Marfan Syndrome {#Sec9}
---------------

Marfan syndrome is an autosomal dominant connective tissue disorder caused by pathogenic variants in *FBN1*. It is characterized by skeletal, ocular, and cardiovascular malformations with wide phenotypic variability. Aortic aneurysm, dissection, and root enlargement are the most commonly reported vascular defects (Dietz et al. [@CR27]; Pyeritz [@CR86]). IBA have been associated with Marfan syndrome through multiple case reports (Finney et al. [@CR30]; Higashida et al. [@CR41]; Matsuda et al. [@CR67]; Ohtsuki et al. [@CR81]; Hainsworth and Mendelow, [@CR38]; Schievink et al. [@CR104]; Stehbens et al. [@CR106]). Conway et al. ([@CR23]) did not find sufficient evidence for an association between intracranial aneurysms and Marfan syndrome upon autopsy of 25 patients. Only one patient autopsied was found to have an intracranial aneurysm, a number that would agree with the general population frequency. However, a recent retrospective chart review of 59 Marfan syndrome patients estimated that 14 % have one or more intracranial aneurysms (Kim et al. [@CR51]). Specific screening for intracranial aneurysms is not routinely recommended in Marfan syndrome patients, though it could be considered in family members affected by Marfan syndrome who also have a first-degree relative affected by IBA, whether or not that family member also has a diagnosis of Marfan syndrome.

Neurofibromatosis Type I {#Sec10}
------------------------

Neurofibromatosis Type I (NF1) is an autosomal dominant condition caused by pathogenic variants in *NF1*. The primary characteristics of NF1 are café-au-lait spots, iris Lisch nodules, and benign neurofibromas (Conway et al. [@CR24]). Vascular abnormalities are also a recognized characteristic of NF1 and patients under 29 years of age have an increased prevalence of IBA relative to the general population risk (Rasmussen et al. [@CR87]). Intracranial aneurysms have been documented as a cerebrovascular feature of NF1 (Friedman et al. [@CR36]; Jett and Friedman [@CR44]). Retrospective reviews of NFI patient data have reported the prevalence of intracranial aneurysms to be between 9 and 11 %. The youngest reported NF1 patient to have an intracranial aneurysm was 1 year of age. However, routine screening for intracranial aneurysms is not recommended for NF1 patients (Muhonen et al. [@CR72]; Rosser et al. [@CR95]; Schievink et al. [@CR105]; Uranishi et al. [@CR109]; Zhao and Han [@CR122]; Zöller et al. [@CR123]). Conway and coauthors (Conway et al. [@CR24]) did not detect any intracranial aneurysms in their autopsy study of 25 NF1 patients between 3 and 69 years of age.

Other Syndromes {#Sec11}
===============

Multiple Endocrine Neoplasia Type I (Adachi et al. [@CR4]), Pseudoxanthoma Elasticum (Allison et al. [@CR6]; Bock and Schwegler [@CR11]; Munyer and Margulis [@CR73]), and Herediatary Hemorrahagic Telangiectasia (HHT) (Willemse et al. [@CR114]) are often mentioned as being associated with IBA. While all have had individual patient case reports which document the presence of intracranial aneurysms, these data are not as robust as are the data for the syndromes listed above and in Table [3](#Tab3){ref-type="table"}. Specific recommendations for IBA screening in these disorders must await larger cohort studies, though in the case of HHT, the currently-recommended screening protocols to detect cerebral arteriovenous malformations (AVM) would be expected to detect IBA as well (McDonald and Pyeritz [@CR68]). Most frequently in HHT patients intracranial aneurysms form along arteries leading into AVM (Willemse et al. [@CR114]). Patients with fibromuscular dysplasia (FMD) are also believed to be at risk for aneurysms in the brain and elsewhere, so current recommendations are that all FMD patients have cross-sectional imaging from head to pelvis with a sensitive method like CTA or MRA (Kadian-Dodov et al. [@CR46]). Though autosomal dominant inheritance has been suggested for fibromuscular dysplasia, definitive genetic candidates have yet to emerge (Kiando et al. [@CR49]). Moyamoya angiopathy, which is also associated with NF1 (Koss et al. [@CR53]), appears to have a pathogenesis that is distinct from that of intracranial berry aneurysms; it is not clear whether the occasional association of intracranial aneurysms with moyamoya (Kawaguchi et al. [@CR48]; Yu et al. [@CR121]) reflects a common pathophysiology at the molecular level, or whether it reflects pathology at one vascular site that perturbs downstream hemodynamics.

Special Counseling Situations {#Sec12}
=============================

Certified genetic counselors will already be thoroughly familiar with family trees that suggest Mendelian inheritance that follows autosomal dominant, autosomal recessive or X-linked patterns of inheritance. Even if a DNA-level diagnosis is not available in those situations, counselors will be able to estimate recurrence risks and suggest appropriate follow-up. Where feasible, risk for apparently-unaffected family members may be refined by imaging studies in their living parents or grandparents. Unusual situations may arise that demand consideration of screening protocols that have not been validated by prospective studies. We are aware of at least two independent families in which a child under age 15 suffered a subarachnoid haemorrhage attributed to a berry aneurysm of the cerebral circulation (Fig. [1](#Fig1){ref-type="fig"}c and unpublished data). Though neither of these children are known to have another affected first-degree relative, it must be borne in mind that rare children who develop diseases that are otherwise considered common among elderly adults may well have an underlying high-penetrance risk allele. Challenging situations such as these may demand a multidisciplinary approach that includes engagement of the genetic counselor with other medical and surgical practitioners involved in the family's care. Co**u**nselors may also need to provide an opinion to insurance providers as to the utility of screening in one family member for the purposes of estimating risk in other family members. In the examples given above, screening of clinically-unaffected sibs may be worthwhile, but screening of clinically-unaffected parents may also provide useful information. Were one or more aneurysms detected in a parent, the unaffected sibs would definitely be considered to be at risk and to merit screening under current guidelines.

Conclusions {#Sec13}
===========

Here we have reviewed and summarized the genetic investigations conducted in sporadic and familial intracranial berry aneurysm populations to date. While several loci and candidate genes have been identified, a conclusive gene-disease association has not yet been made for non-syndromic families. Further next-generation sequencing studies are needed to identify a causative gene in families with intracranial aneurysms as the only clinical finding. Patients with FIA are at increased risk for aneurysm formation and rupture compared to the general population, and screening of all first-degree relatives using MRA or CTA is recommended. Definitive identification of a single-gene cause of FIA in a particular family or group of families would allow genetic confirmation as to which family members are at risk. Family members who did not inherit the pathogenic variant would not need to undergo regular screening, and could obtain peace of mind regarding aneurysm formation later in life. As there is not yet a genetic test, or a conclusive familial recurrence rate, genetic counselors will need to estimate patient risk for developing IBA on a case-by-case basis, through analyzing inheritance within a pedigree. Counselors should also investigate the possibility of an associated syndrome by taking a targeted family history; if warranted by specific findings, they could then refer the patient to a medical geneticist or other suitable specialist.

We have also discussed a number of Mendelian syndromes, primarily hereditary connective tissue disorders, which confer increased risk for IBA development. Of these syndromes, ADPKD has the strongest documented association with IBA. The prevalence estimates of intracranial aneurysms in Marfan syndrome, NF1, EDS, and LDS are likely biased to report a higher percentage of affected patients. In the studies discussed, patients identified as being at risk for vascular complications received brain imaging, whereas patients lacking these risk factors did not receive screening and were not included in the prevalence calculation. Additionally, many of these studies also include fusiform aneurysms when documenting the presence of intracranial aneurysms. These two methodological limitations have prevented an accurate measurement of IBA prevalence in the syndromes listed above, which may or may not be significantly higher than the background population risk. LDS prevalence measurements may not be as affected by these limitations if patients are receiving screening every two years as recommended. It is possible that, as more data is collected on the natural history of this syndrome, LDS will move to a higher risk category for IBA. The heterogeneity of findings on IBA within Marfan syndrome, NF1, EDS, and LDS does not give clear direction to genetic counselors. However, genetic counselors should be aware that patients with these syndromes could be at increased risk for IBA development, and may want to recommend screening for patients who present with additional risk factors such as a specific history of IBA in their family members.
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